The Hollings Cancer Center at MUSC has awarded Dr. Thaxton the 2019-2020 HCC Clinical Concept Award, which provides support for development of clinical trial concepts based on laboratory discoveries. The Thaxton Lab has partnered with TEVA Pharmaceuticals to test the FDA approved drug Omacetaxine for applications in our first immunotherapy clinical trial!
Inhibition of hypoxic conditions has been shown to promote TIL activity. We are partnered with two active clinical trials that treat breast cancer and prostate patients with an anti-hypoxia and/or anti-oxidant drug. We follow patients’ peripheral lymphocyte responses to these combination therapies to monitor immune changes induced by such therapies. Our findings may lead to new combination treatments to promote anti-tumor immunity.
Clinical concept development
We are currently partnered with surgical and medical oncology to bring our novel combination therapy concept to sarcoma patients at MUSC. We aim to modulate metabolism within the sarcoma tumor microenvironment in order to invigorate TIL anti-tumor activity. Stay tuned!